2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Breast Neoplasms
2046
Neoplasms
1460
Carcinoma, Non-Small-Cell Lung
1364
Prostatic Neoplasms
1106
Multiple Myeloma
873
Leukemia, Myeloid, Acute
772
Colorectal Neoplasms
713
Neoplasm Metastasis
704
Lung Neoplasms
697
Melanoma
688
Lymphoma
666
Leukemia
596
Lymphoma, Non-Hodgkin
593
Leukemia, Lymphocytic, Chronic, B-Cell
535
Ovarian Neoplasms
535
Pancreatic Neoplasms
500
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Recurrence
474
Myelodysplastic Syndromes
425
Lymphoma, Follicular
418
Carcinoma, Renal Cell
412
Head and Neck Neoplasms
408
Glioblastoma
380
Lymphoma, Large B-Cell, Diffuse
379
Brain Neoplasms
376
Hodgkin Disease
354
Carcinoma, Hepatocellular
333
Squamous Cell Carcinoma of Head and Neck
326
Lymphoma, Mantle-Cell
306
Sarcoma
286
Interventions
vandetanib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Differentiated Thyroid Cancer
×
Clear all
NCT01876784
2024-07-23
VERIFY
Sanofi
Phase 3
Completed
238 enrolled
12 charts
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts